Dana-Farber Research News 10.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 1 - 15.

By
October 1, 2026
32 min

Dana-Farber

1

The CheckMate-274 trial shows adjuvant nivolumab nearly doubles median disease-free survival in high-risk urothelial carcinoma compared to placebo.
2

Lorlatinib demonstrates unprecedented long-term progression-free survival in advanced ALK-positive non-small-cell lung cancer after 7 years of follow-up.
3

Patients on lorlatinib without progression at 24 months have a 79% probability of survival without progression at year 7.
4

The POSITIVE trial indicates that temporary interruption of adjuvant endocrine therapy for pregnancy is feasible and safe in young women with early breast cancer.
5

Updated results from the POSITIVE trial show similar breast cancer-free and distant recurrence-free interval rates compared to the SOFT/TEXT trials.

Dana-Farber Research News 10.01.2026

1

2

3

4

5

Original Source(s)

Dana-Farber Research News 10.01.2026

Related Content

What Medicare Claims Tell Us About Cancer Disparities in American Indian and Alaska Native Peoples

2026 ASCO Breast Cancer Highlights: Neo-Healer

2026 ASCO Breast Cancer Highlights: HER2CLIMB-05